OS Therapies (OSTX) Competitors $1.45 -0.14 (-8.81%) Closing price 04:00 PM EasternExtended Trading$1.56 +0.12 (+7.93%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock OSTX vs. SLS, FTLF, NKTX, CYBN, TNGX, NLTX, EPRX, ACRS, ADCT, and LRMRShould you be buying OS Therapies stock or one of its competitors? The main competitors of OS Therapies include SELLAS Life Sciences Group (SLS), FitLife Brands (FTLF), Nkarta (NKTX), Cybin (CYBN), Tango Therapeutics (TNGX), Neoleukin Therapeutics (NLTX), Eupraxia Pharmaceuticals (EPRX), Aclaris Therapeutics (ACRS), ADC Therapeutics (ADCT), and Larimar Therapeutics (LRMR). These companies are all part of the "pharmaceutical products" industry. OS Therapies vs. SELLAS Life Sciences Group FitLife Brands Nkarta Cybin Tango Therapeutics Neoleukin Therapeutics Eupraxia Pharmaceuticals Aclaris Therapeutics ADC Therapeutics Larimar Therapeutics OS Therapies (NYSE:OSTX) and SELLAS Life Sciences Group (NASDAQ:SLS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, community ranking, dividends and analyst recommendations. Is OSTX or SLS more profitable? OS Therapies' return on equity of 0.00% beat SELLAS Life Sciences Group's return on equity.Company Net Margins Return on Equity Return on Assets OS TherapiesN/A N/A -569.57% SELLAS Life Sciences Group N/A -629.46%-178.65% Do insiders & institutionals have more ownership in OSTX or SLS? 17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 13.8% of OS Therapies shares are held by insiders. Comparatively, 1.4% of SELLAS Life Sciences Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has higher earnings and valuation, OSTX or SLS? OS Therapies has higher earnings, but lower revenue than SELLAS Life Sciences Group. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than OS Therapies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOS TherapiesN/AN/A-$7.79M-$0.86-1.69SELLAS Life Sciences Group$1M169.62-$37.34M-$0.38-4.47 Does the media prefer OSTX or SLS? In the previous week, OS Therapies and OS Therapies both had 4 articles in the media. SELLAS Life Sciences Group's average media sentiment score of 0.58 beat OS Therapies' score of -0.17 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OS Therapies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SELLAS Life Sciences Group 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer OSTX or SLS? OS Therapies received 2 more outperform votes than SELLAS Life Sciences Group when rated by MarketBeat users. Likewise, 100.00% of users gave OS Therapies an outperform vote while only 55.56% of users gave SELLAS Life Sciences Group an outperform vote. CompanyUnderperformOutperformOS TherapiesOutperform Votes12100.00% Underperform VotesNo VotesSELLAS Life Sciences GroupOutperform Votes1055.56% Underperform Votes844.44% Do analysts prefer OSTX or SLS? OS Therapies presently has a consensus target price of $18.00, suggesting a potential upside of 1,141.38%. Given OS Therapies' stronger consensus rating and higher possible upside, equities research analysts clearly believe OS Therapies is more favorable than SELLAS Life Sciences Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OS Therapies 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40SELLAS Life Sciences Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryOS Therapies beats SELLAS Life Sciences Group on 10 of the 15 factors compared between the two stocks. Get OS Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for OSTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OSTX vs. The Competition Export to ExcelMetricOS TherapiesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$31.41M$6.52B$5.37B$19.41BDividend YieldN/A2.65%5.22%3.83%P/E Ratio-1.698.9226.8434.23Price / SalesN/A253.80392.3434.85Price / CashN/A65.8538.2517.51Price / BookN/A6.466.794.69Net Income-$7.79M$143.98M$3.23B$1.02B7 Day Performance-19.44%3.04%4.07%-1.34%1 Month Performance-2.68%7.44%12.52%9.79%1 Year PerformanceN/A-2.46%16.83%3.27% OS Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OSTXOS Therapies2.0506 of 5 stars$1.45-8.8%$18.00+1,141.4%N/A$31.41MN/A-1.69N/AGap UpSLSSELLAS Life Sciences Group0.3176 of 5 stars$1.54-1.3%N/A+31.1%$145.60M$1M-2.2310Gap UpFTLFFitLife Brands4.4273 of 5 stars$15.41-1.9%$20.50+33.0%+0.9%$144.61M$64.47M18.2420Earnings ReportNKTXNkarta1.9701 of 5 stars$2.02+4.7%$14.83+634.3%-73.3%$143.34MN/A-1.07140News CoveragePositive NewsEarnings ReportAnalyst RevisionGap UpCYBNCybin2.7205 of 5 stars$6.62-6.1%$86.00+1,199.1%N/A$142.18MN/A-1.5150News CoverageTNGXTango Therapeutics1.5872 of 5 stars$1.31+14.9%$12.33+841.5%-73.0%$141.62M$42.07M-1.1190NLTXNeoleukin TherapeuticsN/A$14.73-1.8%N/A-42.6%$138.43MN/A-4.7490Gap UpHigh Trading VolumeEPRXEupraxia Pharmaceuticals2.2192 of 5 stars$3.86+1.4%$10.50+172.4%+32.2%$138.20MN/A-5.3529Gap UpACRSAclaris Therapeutics2.8746 of 5 stars$1.25-0.8%$10.67+753.3%+13.4%$135.35M$18.72M-2.40100Gap UpADCTADC Therapeutics2.6699 of 5 stars$1.35+5.9%$7.75+476.2%-47.8%$133.39M$70.84M-0.56310News CoverageEarnings ReportAnalyst RevisionLRMRLarimar Therapeutics2.0664 of 5 stars$2.08-1.9%$19.63+843.5%-71.7%$133.18MN/A-1.8130Positive News Related Companies and Tools Related Companies SELLAS Life Sciences Group Competitors FitLife Brands Competitors Nkarta Competitors Cybin Competitors Tango Therapeutics Competitors Neoleukin Therapeutics Competitors Eupraxia Pharmaceuticals Competitors Aclaris Therapeutics Competitors ADC Therapeutics Competitors Larimar Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:OSTX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OS Therapies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share OS Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OSTX Stock Free OSTX Stock Alerts